At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 312 enrolled
Drug / intervention
GSK2036874A vaccine +2 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Immunogenicity and Reactogenicity of a Booster Dose of GlaxoSmithKline Biologicals' GSK2036874A Vaccine in Healthy Toddlers
In Brief
A Phase 2 clinical trial evaluating GSK2036874A vaccine, Zilbrix™/Hib vaccine, and 1 other intervention for Haemophilus Influenzae Type b and 5 related conditions. Completed, enrolled 312 participants across 1 site.
Detailed Summary
The purpose of the study is to assess the immunogenicity and safety of three formulations of GSK Biologicals' GSK2036874A vaccine compared to Zilbrix™/Hib and Poliorix™ vaccines administered concomitantly, when administered as a single booster dose to healthy poliovirus-primed toddlers aged 12-24 months.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHaemophilus Influenzae Type b, Tetanus, Hepatitis B, Whole Cell Pertussis, Diphtheria, Poliomyelitis Vaccines
CountriesPhilippines
Collaborators--
Timeline
Phase 2CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedApr 2010
Enrollment StartMay 2010
Primary CompletionSep 2010
TodayJul 2026
First PostedApr 19, 2010
Enrollment StartMay 13, 2010
Primary CompletionSep 2, 2010
TodayJul 2, 2026
Enrollment to primary: 4 monthsPosted 16.2 years ago
Interventions
GSK2036874A vaccinebiological
Intramuscular, single dose
Zilbrix™/Hib vaccinebiological
Intramuscular, single dose
Poliorix™biological
Intramuscular, single dose